Login / Signup

En bloc resection of bladder tumors: challenges and unmet needs in 2022.

Evangelos N SymeonidisKa-Lun LoKa-Lun ChuiIoannis VakalopoulosPetros Sountoulides
Published in: Future oncology (London, England) (2022)
Non-muscle invasive bladder cancer accounts for the majority of new bladder cancer diagnoses, and endoscopic transurethral resection of bladder tumor (TURBT) represents the standard-of-care. Although a relatively safe and common procedure, TURBT is often hampered by the questionable quality of resection. The evolution of surgical techniques has brought en bloc resection of bladder tumor (ERBT) to the forefront. ERBT has emerged as an alternative to conventional TURBT, incorporating a more delicate en bloc sculpting and tumor excision, in contrast to 'piecemeal' resection by conventional TURBT. ERBT appears safe, feasible and effective with demonstrably higher rates of detrusor muscle in the pathologic specimen, all while providing better staging and obviating the need for a re-TURBT in selected patients. However, the method's adoption in the field is still limited. This review summarizes the recent evidence relevant to ERBT while further highlighting the technique's limitations and unmet needs.
Keyphrases
  • muscle invasive bladder cancer
  • spinal cord injury
  • end stage renal disease
  • newly diagnosed
  • skeletal muscle
  • ejection fraction
  • lymph node
  • minimally invasive
  • ultrasound guided
  • urinary tract
  • locally advanced